The AlphaLISA™ SureFire® Ultra™ Human Total ErbB3 assay is a sandwich immunoassay for quantitative detection of total ErbB3 in cellular lysates using Alpha Technology.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Receptor tyrosine-protein kinase erbB3, also known as HER3 (human epidermal growth factor receptor 3) is a membrane bound protein that is encoded by the ERBB3 gene. ErbB3 has a neuregulin binding domain, however, does not have an active kinase domain and can therefore bind this ligand but is unable to convey the signal into the cell through protein phosphorylation. ErbB3 forms heterodimers with other EGF receptor family members which have kinase activity. Heterodimerization leads to the activation of pathways that trigger cell proliferation or differentiation. ErbB3 overexpression is an indicator of poor patient prognosis in human breast cancer and has also been reported in other cancers such as prostate and bladder.
The AlphaLISA SureFire Ultra Human Total ErbB3 Detection Kit is a sandwich immunoassay for the quantitative detection of total ErbB3 in cellular lysates, using Alpha Technology.
Application |
Protein Analysis & Detection
Protein Detection
|
---|---|
Assay Points |
500
|
Assay Target |
ErbB3
|
Assay Target Class |
Phospho-protein
|
Assay Technology |
Alpha
|
Automation Compatible |
Yes
|
Brand |
AlphaLISA SureFire Ultra
|
Detection Method |
Alpha
|
Experimental Type |
In vitro
|
Shipping Conditions |
Shipped in Blue Ice
|
Target Species |
Human
|
Therapeutic Area |
Oncology
|
Unit Size |
500 Assay Points
|
Discover Alpha SureFire® Ultra™ assays, the no-wash cellular kinase assays leveraging Revvity's exclusive bead-based technology...
Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.
We are here to answer your questions.